Although increased MYBL2 expression in prostate cancer is linked to resistance to androgen receptor signaling inhibitors (ARSI), it remains unknown if MYBL2 mechanistically increases the potential for prostate cancer to activate alternate lineages within the phenotypic plasticity spectrum when progressing on AR-targeted treatments. This evidence concerns the gene AR and prostate carcinoma.